5 Key Takeaways

• 1

  ONL1204, a Fas inhibitor, showed significant reductions in geographic atrophy lesion growth in a phase 1b clinical trial.

• 2

  Patients receiving ONL1204 had up to a 50% reduction in lesion growth compared to sham-treated eyes after two injections.

• 3

  The study indicated that ONL1204 was safe and well tolerated, with minimal treatment-emergent adverse events reported.

• 4

  Exploratory analyses using AI tools correlated biomarker findings with structural and functional improvements in treated eyes.

• 5

  Future phase 2 studies will further investigate ONL1204's neuroprotective potential across various ophthalmic diseases.